-
公开(公告)号:US12081979B2
公开(公告)日:2024-09-03
申请号:US17090385
申请日:2020-11-05
IPC分类号: H04W12/06 , H04L9/40 , H04W12/084 , H04W12/71
CPC分类号: H04W12/068 , H04L63/0884 , H04L63/10 , H04W12/084 , H04W12/71
摘要: Authentication of an Internet-of-Things (IoT) device comprises receiving, by a proxy application executing on a mobile device during a registration process, a device identifier associated with the IoT device. The proxy application transmits the device identifier to a router of the wireless network. The proxy application receives the device identifier from the router in response to the router receiving an authorization request with no network password from the IoT device for access to the wireless network, where the router forwards the device identifier to the proxy application. The proxy application prompts the user of the mobile device to enter the password, and transmits the entered network password to the router, such that the router validates the password and grants the IoT device access to the wireless network, the IoT device transmits the IoT device identifier to the router for subsequent network connection without a need for the mobile device.
-
公开(公告)号:US12024570B2
公开(公告)日:2024-07-02
申请号:US17070129
申请日:2020-10-14
发明人: Aynur Hermann , Ella Ioffe , Elena Burova , Gavin Thurston , William Olson
CPC分类号: C07K16/40 , A61K39/395 , A61P35/00 , C07K16/2818 , C12N15/62 , A61K2039/507 , A61K2039/545 , A61K2300/00 , C07K16/2809 , C07K16/2863 , C07K16/2887 , C07K2317/21 , C07K2317/33 , C07K2317/76 , C07K2317/92
摘要: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
-
公开(公告)号:USD1027313S1
公开(公告)日:2024-05-14
申请号:US29817859
申请日:2021-12-03
设计人: Dayong Zhang
摘要: FIG. 1 is a perspective view of a powder compact according to the present application;
FIG. 2 is a front view thereof;
FIG. 3 is a rear view thereof;
FIG. 4 is a left side view thereof;
FIG. 5 is a right side view thereof;
FIG. 6 is a top view thereof; and,
FIG. 7 is a bottom view thereof.
The portion of the powder compact encircled by broken lines forms no part of the claimed design.-
公开(公告)号:US11926670B2
公开(公告)日:2024-03-12
申请号:US17342949
申请日:2021-06-09
发明人: Daniel B. Dix , Xiaolin Tang
IPC分类号: C07K16/28 , A61K9/00 , A61K39/395 , A61K47/18 , A61M5/315
CPC分类号: C07K16/2866 , A61K9/0019 , A61K39/39591 , A61K47/183 , A61M5/315 , C07K2317/21 , C07K2317/56 , C07K2317/94
摘要: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
-
公开(公告)号:USD1010687S1
公开(公告)日:2024-01-09
申请号:US29833565
申请日:2022-04-05
申请人: CQMS Pty Ltd
设计人: Samuel Beck , Ian Ashby , David Hume , Brendan Waterman , Bruce Lilley , Todd Lawler
摘要: FIG. 1 is a bottom view of a wear member, showing our new design;
FIG. 2 is a left side view thereof;
FIG. 3 is a right side view thereof;
FIG. 4 is a top sectional view thereof, taken along line A-A in FIG. 5;
FIG. 5 is another left side view thereof, the broken line labeled as A-A and B-B indicates a sectional view plane and forms no part of the claimed design;
FIG. 6 is a bottom sectional view thereof, taken along line B-B in FIG. 5;
FIG. 7 is a left rear lower perspective view thereof;
FIG. 8 is a right rear lower perspective view thereof;
FIG. 9 is a left rear upper perspective view thereof;
FIG. 10 is a right rear upper perspective view thereof;
FIG. 11 is a right rear view thereof;
FIG. 12 is a rear view thereof;
FIG. 13 is a left rear view thereof; and,
FIG. 14 is a front view thereof.
The broken lines in the drawings depict portions of the wear member that form no part of the claimed design.-
公开(公告)号:USD1010075S1
公开(公告)日:2024-01-02
申请号:US35514086
申请日:2021-10-22
摘要: Fig. 1.1 is a front elevation view showing our new design;
Fig. 1.2 is a rear elevation view thereof;
Fig. 1.3 is a left side elevation view thereof;
Fig. 1.4 is a right side elevation view thereof;
Fig. 1.5 is a top plan view thereof; and
Fig. 1.6 is a top perspective view thereof.
The broken lines depict features of the washbasin that form no part of the claimed design.-
公开(公告)号:US11860651B2
公开(公告)日:2024-01-02
申请号:US17423095
申请日:2020-01-20
发明人: Yimin Fang , Dongsheng Yao , Guanjin Zhong
摘要: An adjustment position of a water output device is provided. A flow volume adjustment component of the water output device has a first position corresponding to a flow volume greater than zero; upon detecting that the flow volume adjustment component reduces the flow volume to that corresponding to the first position, a detection component sends a signal to a control component; and the control component-turns off an electronic waterway switch according to the signal. In this way, when the flow volume is reduced, the electronic waterway switch can be turned off by signal control, and in this case, the flow volume adjusted by the flow volume adjustment component is kept at a particular value, such that the next time water is output by a user using an electronic mode, the failure of water output would not occur.
-
公开(公告)号:US11667701B2
公开(公告)日:2023-06-06
申请号:US17041595
申请日:2019-03-22
发明人: Lisa Purcell
IPC分类号: C07K16/20 , A61K9/00 , A61K39/015
CPC分类号: C07K16/205 , A61K9/0019 , A61K39/015 , C07K2317/14 , C07K2317/31 , C07K2317/565 , C07K2317/73 , C07K2317/92
摘要: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to Plasmodium falciparum reticulocyte binding protein homologue 5 (PfRH5), compositions thereof and methods of making such antibodies, fragments and compositions. Method and compositions for treating, preventing or diagnosing Plasmodium falciparum infection and malaria are also part of the present invention.
-
公开(公告)号:US11651462B2
公开(公告)日:2023-05-16
申请号:US16736668
申请日:2020-01-07
发明人: Michael Hsiang Tsung , Tselmeg Otgonbayar Shponko , Ratinder Bedi , Girish Ramachandran , Martin Charles Elliott
IPC分类号: G06N20/00 , G06Q50/26 , G06Q20/40 , G06N20/20 , G06Q30/018 , G06F18/214 , G06F18/2413 , G06F18/243
CPC分类号: G06Q30/0185 , G06F18/214 , G06F18/24147 , G06F18/24323 , G06N20/00 , G06N20/20 , G06Q20/4016 , G06Q30/018 , G06Q50/265
摘要: Methods and systems are described. A method includes accessing training data samples that includes a plurality of transaction laundering associated features and generating random samples, training a first plurality of different models to identify transaction laundering merchants based on random samples generated from each of the training data samples, training a second plurality of different models to identify the transaction laundering merchants based on the training data, generating a transaction laundering classification for a merchant from each of the first plurality of models and each of the second plurality of models, generating a first model group classification based on a first majority vote on transaction laundering classifications from the first plurality of models, and generating a second model group classification based on a second majority vote on transaction laundering classifications from the second plurality of models. A likelihood that the merchant is a transaction launderer is determined.
-
公开(公告)号:US11642390B2
公开(公告)日:2023-05-09
申请号:US17167990
申请日:2021-02-04
发明人: Panayiotis Stevis , Andrew J. Murphy , Jesper Gromada , Yonaton Ray , Jee H. Kim , Ivan B. Lobov
IPC分类号: A61K39/395 , A61K38/22 , A61K38/08 , A61K38/10 , A61K47/64 , A61P9/04 , A61P9/08 , A61P9/10 , C07K16/28 , C07K7/06 , C07K7/08 , C07K14/575 , C07K19/00 , C07K14/705 , C07K14/72 , A61P37/02 , A61P35/00 , A61K38/00 , C07K14/47 , C07K16/46
CPC分类号: A61K38/08 , A61K38/10 , A61K38/22 , A61K39/3955 , A61K47/64 , A61P9/04 , A61P9/08 , A61P9/10 , C07K16/2869 , A61K38/00 , A61P35/00 , A61P37/02 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/575 , C07K14/705 , C07K14/72 , C07K16/28 , C07K16/46 , C07K19/00 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/74
摘要: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.
-
-
-
-
-
-
-
-
-